Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.

ABSTRACT:

Background

We report copy-number profiling by low-pass WGS (LP-WGS) in individual circulating tumour cells (CTCs) for guiding treatment in patients with metastatic breast cancer (MBC), comparing CTC results with mutations detected in circulating tumour DNA (ctDNA) in the same blood samples.

Methods

Across 10 patients with MBC who were progressing at the time of blood sampling and that had >20 CTCs detected by CellSearch^®, 63 single cells (50 CTCs and 13 WBCs) and 16 cell pools (8 CTC pools and 8 WBC pools) were recovered from peripheral blood by CellSearch^®/DEPArray™ and sequenced with Ampli1 LowPass technology (Menarini Silicon Biosystems). Copy-number aberrations were identified using the MSBiosuite software platform, and results were compared with mu

SUBMITTER: Fernandez-Garcia D 

PROVIDER: S-EPMC9643413 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature